DEA permits GW Pharma to sell cannabis derived drug, CEO says there is an 'acute need' for the medic
CNBC Television | Published on Sep 27, 2018
CNBC's Meg Tirrell reports that the Drug Enforcement Administration recently approved GW Pharma to sell a new cannabis derived drug. The company's CEO, Justin Gover, said that people suffering from epilepsy have been waiting for the medication to be approved.
- Numbmonk, I think you may be onto something very significant with your post that has key thoughts which are worth reflecting on after viewing the 3 YT clips above. GW Pharmaceuticals' Epidiolex was the first CBD oil to receive FDA approval and DEA rescheduling. In the second YT clip, notice how the GW CEO says that if you apply the rigours of science and law to cannabis research, the FDA and DEA will act and respond to the needs of patients.
- The important point is the pharma grade aspect of producing the CBD oil which I think may have been important to the recent conditional approval of the application in Virginia for BLDV's client; this shows the potential demand for this approach. It will be interesting to see how Cann10's Cannareet enters the North American market. Notice how the licensing of Cannareet is regularly mentioned in previous BLDV PRs - one of which was related to the Virginia application, see highlights posts below:
Blue Diamond Ventures, Inc. seeks to partner with individuals and companies that share a common synergy, mission and vision to enable pharmaceutical-grade cannabis products/services that are produced, delivered and consumed utilizing fewer natural resources. Blue Diamond Ventures Inc. seeks opportunities in medical cannabis markets and is driven bycritical thinking and the scientific method.
iii) Production: Cann10 is interested in taking an equity position in production facilities worldwide. We bring extensive experience, a well developed building, outfitting and preparation program together with the expertise to cut the time needed to turn an empty space into a revenue generating facility. We do not provide this as a service, but will provide the necessary know-how, plants, technologies and techniques to farms in which we are partners. We are currently involved in new projects in Canada, Portugal, Australia and other locations.
5.5 Cannareet and Israeli technologies: Certified by Israel Ministry of Health GAP and GMP as well as other local authorities. Developed in cann10’s own labs, Cannareet products are ideal for dispensaries and for retail use where allowed by law. Cannareet will feature oils, vapes, flowers, cigarettes and caplets available. Special orders can be prepared based on a minimum quantity.
News 
Market Data 
Discover 
